Niemann-Pick Diseases

Return to The Medical Biochemistry Page Protection Status
© 1996–2017, LLC | info @

Introduction to the Niemann-Pick Diseases

The Niemann-Pick (NP) diseases are a group of autosomal recessive disorders that belong to a family of disorders identified as lysosomal storage diseases. There are two distinct sub-families of NP diseases. Niemann-Pick type A (NPA) and type B (NPB) diseases are caused by defects in the acid sphingomyelinase gene (ASM). Niemann-Pick type C1 (NPC1) disease is caused by defects in a gene involved in LDL-cholesterol homeostasis identified as the NPC1 gene.

Reaction catalyzed by acid sphingomyelinase

Activity of Acid Sphingomyelinase

Niemann-Pick Disease, Types A and B

Both Niemann-Pick disease type A and type B are caused by defects in the lysosomal hydrolase, acid sphingomyelinase, ASMase (gene symbol: SMPD1, sphingomyelin phosphodiesterase-1). The SMPD1 gene is located on chromosome 11p15.4–p15.1 spanning 5 kb and composed of 6 exons that generate two alternatively spliced mRNAs. These mRNAs encode ASMase isoform 1 which is a 631 amino acid glycoprotein and ASMase isoform 2 which is a 620 amino acid glycoprotein. At least 18 mutations have been identified in the SMPD1 gene resulting in types A and B NP disease. There are three disease alleles that represent greater than 90% of the cases of type A NP disease in Ashkenazi Jewish populations. These disease alleles include a single nucleotide deletion resulting in a frame-shift at proline 330 (fsP330) and two different missense mutations, one leading to the substitution of leucine for proline at amino acid 302 (L302P) and the other leading to substitution of arginine for leucine at amino acid 496 (R496L). The carrier allele frequency for these type A mutations is as high as 1 in 80 in Ashkenazi Jewish populations. A single mutation, a 3-base deletion leading to loss of arginine at what would be amino acid position 608 (ΔR608), is commonly associated with type B NP disease. This latter mutation leaves the ASMase protein with sufficient residual activity to afford protection from the severe neurological symptoms associated with type A NP disease.

Type A NP disease is associated with a rapidly progressing neurodegeneration leading to death by 2 to 3 years of age. In contrast, type B NP disease has a variable phenotype marked primarily by visceral involvement with little to no neurological detriment. Diagnosis of type B NP disease is usually made in early childhood by the presence of hepatosplenomegaly. The most severely affected type B patients exhibit a progressive pulmonary involvement. Both type A and type B NP disease are characterized by the presence of the "Niemann-Pick" cell. This histologically distinct cell type is of the monocyte-macrophage lineage and is a characteristic lipid-laden foam cell.

The course of type A NP disease is rapid. Infants are born following a typically normal pregnancy and delivery. Within 4–6 months the abdomen protrudes and hepatosplenomegaly will be diagnosed. The early neurological manifestations include hypotonia, muscular weakness and difficulty feeding. As a consequence of the feeding difficulties and the swollen spleen, infants will exhibit a decrease in growth and body weight. By the time afflicted infants reach 6 months of age the signs of psycho-motor deterioration become evident. The infant becomes weaker and progressively hypotonic. Previous developmental milestones such as sitting alone begin to be lost. Ophthalmic examination reveals a cherry-red spot typical of patients with Tay-Sachs disease (another lysosomal storage disease) in about 50% of type A NP disease infants. As the disease progresses spasticity and rigidity increase and infant experience complete loss of contact with their environment. As indicated above, type B NP disease has a much more variable phenotype and most patients do not have neurological involvement and are intellectually normal. There is currently no therapy for either type A or type B NP disease.

Niemann-Pick Disease, Type C1

Niemann-Pick disease type C1 (NPC1) results from an error in the trafficking of exogenous cholesterol, thus it is more commonly referred to as a lipid trafficking disorder even though it belongs to the family of lysosomal storage diseases. The principle biochemical defect in patients with NPC is an accumulation of cholesterol, sphingolipids, and other lipids in the late endosomes/lysosomes (LE/L) of all cells. NPC is a disease characterized by fatal progressive neurodegeneration.

The gene, whose mutations lead to NPC1, is identified as NPC1 and is located on chromosome 18q11.2 spanning 47 kb and composed of 28 exons that encode a 1278 amino acid precursor protein. To date more than 200 mutations in the NPC1 gene have been identified in NPC afflicted individuals. The most prevalent mutations are point mutations and many afflicted individuals are genotypic compound heterozygotes harboring at least two of the mutations. The eight most common point mutations identified are at nucleotides:

530 [a G to A (G>A) mutation resulting in cysteine 177 change to tyrosine (Cys177Tyr)]

2324 (A>C resulting in Gln775Pro)

2974 (G>T resulting in Gly992Trp)

2974 (G>C resulting in Gly992Arg)

2974 (G>A resulting in Gly992Arg)

3019 (C>G resulting in Pro1007Ala)

3160 (G>A resulting in Ala1054Thr)

3182 (T>C resulting in Ile1061Thr).

Several additional point mutations have been identified in the NPC1 gene but they do not manifest with disease.

The NPC1 gene encodes a 1278 amino acid protein that contains regions of homology to mediators of cholesterol homeostasis suggesting why LDL-cholesterol accumulates in lysosomes of afflicted individuals. Within the protein are regions of homology to the transmembrane domain of the morphogen receptor patched (of Drosophila melanogaster) and the sterol-sensing domains (SSDs) of SCAP (SREBP cleavage-activating protein; SREBP=sterol regulated element binding protein) and HMG-CoA reductase (HMGR). The NPC1 encoded protein is an integral membrane protein containing 13 putative transmembrane domains. The protein is primarily associated with intralumenal vesicles and multi-vesicular late endosomes. The transmembrane regions of NPC1 are separated by three lumenal loops that contain sites of glycosylation. NPC1 also transiently cycles through the trans-Golgi network. The SSD of NPC1 is composed of 5 of the 13 transmembrane domains. Unlike the SSDs in SCAP and HMGR, the NPC1 SSD does not bind the Insig proteins but does bind cholesterol esters and oxysterols. Mutations in the SSD of NPC1 are commonly found in NPC1 patients. The major function of NPC1 is to facilitate the movement of cholesterol out of LE/L.

At least 95% of NPC1 patients contain mutations in the NPC1 locus with the remainder harboring mutations in a second gene identified as NPC2. The NPC2 locus is located on chromosome 14q24.3 spanning 13.5 kb and composed of 5 exons encoding a lysosomal glycoprotein of 151 amino acids. The NPC2 protein was originally identified as epididymal secretory protein (HE1). Like the protein encoded by the NPC1 locus, the NPC2 gene product also binds cholesteryl esters. However, unlike NPC1, NPC2 does not bind oxysterols. The NPC2 protein is a soluble protein found in the lumen of lysosomes. The NPC2 protein is targeted to the lysosomes by binding the mannose-6-phosphate receptor. The NPC2 protein is involved in cholesterol movement out of LE/L in conjunction with NPC1.

One model proposed for the combined actions of NPC1 and NPC2 is that membrane bound NPC1 interacts with cholesterol that has accumulated in intralumenal vesicle membranes and then transfers the cholesterol to soluble NPC2. The action of NPC2 is then to transfer the cholesterol to the limiting membranes of LE/L which allows for cholesterol distribution to other cellular membranes. An alternative model proposes that NPC2 removes cholesterol from intralumenal vesicles of LE/L and then transfers the cholesterol to NPC1 in the limiting membranes of the LE/L.

A gene related to the NPC1 gene is called Niemann-Pick type C1-like 1 (NPC1L1). This gene is expressed in the brush border cells of the small intestine and is involved in intestinal absorption of cholesterol. The cholesterol lowering action of the drug ezemitibe (Zetia®) stems from the fact that the drug binds to and interferes with the cholesterol absorption functions of NPC1L1. NPC1L1 is also highly expressed in human liver.

A genetic isolate of Niemann-Pick disease, first identified in patients in Colorado and Nova Scotia, Canada, was originally called Niemann-Pick type D (NPD) disease. However, these patients are now known to have harbored specific alleles of the NPC1 locus.

The prevalence of NPC1 disease is more common than NPA and NPB disease combined, however, as indicated above for NPA, certain ethnic groups have significant disease allele carrier frequency. There can be significant clinical heterogeneity associated with NPC disease. Most afflicted individuals have progressive neurological disease with early lethality. The characteristic phenotypes associated with "classic" NPC1 disease are variable hepatosplenomegaly, progressive ataxia, dystonia, dementia and vertical supranuclear gaze palsy (VSGP). These individuals will present in childhood and death will ensue by the second or third decade. Because of the variable clinical phenotypes of NPC1 disease it has been sub-divided into five presentation classifications: perinatal, early infantile, late infantile, juvenile and adult. VSGP is a characteristic neurological manifestation in NPC1 disease being found in virtually all juvenile and adult cases of the disease. Like NPA and NPB disease, NPC1 pathology is characterized by the presence of lipid-laden foam cells in the visceral organs and the nervous system. There is currently no specific treatment for NPC1 disease.












return to Inborn Errors page
return to Sphingolipids page
Return to The Medical Biochemistry Page
Michael W King, PhD | © 1996–2017, LLC | info @

Last modified: April 4, 2017